Qualigen Therapeutics announced it has completed its in vivo efficacy analysis of QN-247 in solid tumors.

The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have divulged thienyl and cycloalkyl aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatment of cancer and fibrosis.

IFM Due has presented new stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer.

BeiGene has divulged new GTPase KRAS (G12A mutant) inhibitors reported to be useful for the treatment of cancer.

The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have discovered isoindolinone aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatement of cancer and fibrosis.

Jing Medicine Technology has described new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a mothers against decapentaplegic homolog 3 (SMAD3)-targeting moiety through a linker reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and autoimmune disease.